|
US3152180A
(en)
|
1960-08-25 |
1964-10-06 |
Studiengesellschaft Kohle Mbh |
Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
|
|
US3391142A
(en)
|
1966-02-09 |
1968-07-02 |
Lilly Co Eli |
Adamantyl secondary amines
|
|
GB1175820A
(en)
|
1966-02-18 |
1969-12-23 |
Upjohn Co |
Amino-Adamantane Derivatives
|
|
ES413944A1
(es)
|
1972-04-20 |
1976-06-01 |
Merz & Co |
Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
|
|
US3992518A
(en)
|
1974-10-24 |
1976-11-16 |
G. D. Searle & Co. |
Method for making a microsealed delivery device
|
|
US4284444A
(en)
|
1977-08-01 |
1981-08-18 |
Herculite Protective Fabrics Corporation |
Activated polymer materials and process for making same
|
|
US4148896A
(en)
|
1978-02-22 |
1979-04-10 |
E. I. Du Pont De Nemours And Company |
Antidepressant combination
|
|
DE2856393C2
(de)
|
1978-12-27 |
1983-04-28 |
Merz + Co GmbH & Co, 6000 Frankfurt |
Arzneimittel zur Behandlung von Morbus Parkinson
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4346112A
(en)
|
1981-06-29 |
1982-08-24 |
University Patents Inc. |
Composition and method for treating patients having Parkinson's Disease
|
|
JPS584718A
(ja)
|
1981-06-30 |
1983-01-11 |
Nippon Chibagaigii Kk |
新規適応症に用うる医薬製剤
|
|
DK150008C
(da)
|
1981-11-20 |
1987-05-25 |
Benzon As Alfred |
Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
|
|
US5366738A
(en)
|
1982-07-29 |
1994-11-22 |
Merck & Co., Inc. |
Controlled release drug dispersion delivery device
|
|
JPS61502760A
(ja)
|
1984-07-24 |
1986-11-27 |
キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド |
粘着性経皮投与層
|
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
|
IT1188212B
(it)
|
1985-12-20 |
1988-01-07 |
Paolo Colombo |
Sistema per il rilascio a velocita' controllata di sostanze attive
|
|
EP0241809B1
(de)
|
1986-04-16 |
1990-08-08 |
ASTA Pharma Aktiengesellschaft |
Synergistische Kombination von Amantadin und Selegilin
|
|
GB8613689D0
(en)
*
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
|
GB8807504D0
(en)
|
1988-03-29 |
1988-05-05 |
Sandoz Ltd |
Improvements in/relating to organic compounds
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
US5330766A
(en)
*
|
1989-01-06 |
1994-07-19 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
|
US5202128A
(en)
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
|
US5334618A
(en)
|
1991-04-04 |
1994-08-02 |
The Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
|
DE58905637D1
(de)
|
1989-04-14 |
1993-10-21 |
Merz & Co Gmbh & Co |
Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
|
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
|
WO1991006291A1
(fr)
|
1989-10-26 |
1991-05-16 |
Nippon Shinyaku Co., Ltd. |
Preparation a liberation entretenue
|
|
IT1237904B
(it)
|
1989-12-14 |
1993-06-18 |
Ubaldo Conte |
Compresse a rilascio a velocita' controllata delle sostanze attive
|
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
|
US5192550A
(en)
*
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
|
US5221536A
(en)
*
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
|
US5057321A
(en)
*
|
1990-06-13 |
1991-10-15 |
Alza Corporation |
Dosage form comprising drug and maltodextrin
|
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
|
GB9104854D0
(en)
|
1991-03-07 |
1991-04-17 |
Reckitt & Colmann Prod Ltd |
Sustained release compositions
|
|
US5614560A
(en)
|
1991-04-04 |
1997-03-25 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
|
US5326570A
(en)
*
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
|
KR100221695B1
(ko)
|
1991-08-12 |
1999-09-15 |
그린 마틴, 브라이언 쥐 테슬리 |
약학적 구상 제형
|
|
DE4225730C2
(de)
|
1992-08-04 |
2003-04-30 |
Merz Pharma Gmbh & Co Kgaa |
Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
|
|
US5358721A
(en)
*
|
1992-12-04 |
1994-10-25 |
Alza Corporation |
Antiviral therapy
|
|
EP0711166A1
(en)
|
1993-07-22 |
1996-05-15 |
Warner-Lambert Company |
Controlled release tacrine drug delivery systems and methods for preparing same
|
|
PT729351E
(pt)
|
1993-11-16 |
2000-12-29 |
Skyepharma Inc |
Vesiculas com libertacao controlada de activos
|
|
US5395626A
(en)
*
|
1994-03-23 |
1995-03-07 |
Ortho Pharmaceutical Corporation |
Multilayered controlled release pharmaceutical dosage form
|
|
DE4413350A1
(de)
|
1994-04-18 |
1995-10-19 |
Basf Ag |
Retard-Matrixpellets und Verfahren zu ihrer Herstellung
|
|
US5660848A
(en)
|
1994-11-02 |
1997-08-26 |
The Population Council, Center For Biomedical Research |
Subdermally implantable device
|
|
US20020006438A1
(en)
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
|
US5677349A
(en)
|
1995-04-27 |
1997-10-14 |
Gilad; Gad M. |
Agmatine for the treatment of neurotrauma and neurodegenerative diseases
|
|
DE19528388A1
(de)
|
1995-08-02 |
1997-02-06 |
Hans Peter Prof Dr Med Zenner |
Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
|
|
AUPN605795A0
(en)
|
1995-10-19 |
1995-11-09 |
F.H. Faulding & Co. Limited |
Analgesic pharmaceutical composition
|
|
US6395292B2
(en)
|
1996-02-02 |
2002-05-28 |
Alza Corporation |
Sustained delivery of an active agent using an implantable system
|
|
WO1997045091A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Euro-Celtique, S.A. |
Sustained release oxycodone formulations with no fed/fast effect
|
|
CA2264182A1
(en)
*
|
1996-08-23 |
1998-02-26 |
Algos Pharmaceutical Corporation |
Anticonvulsant containing composition for treating neuropathic pain
|
|
US5891885A
(en)
*
|
1996-10-09 |
1999-04-06 |
Algos Pharmaceutical Corporation |
Method for treating migraine
|
|
US5919826A
(en)
*
|
1996-10-24 |
1999-07-06 |
Algos Pharmaceutical Corporation |
Method of alleviating pain
|
|
ATE314054T1
(de)
*
|
1996-10-25 |
2006-01-15 |
Shire Lab Inc |
Osmotisches verabreichungssystem für lösliche dosen
|
|
DE19644998C1
(de)
|
1996-10-30 |
1998-06-10 |
Hanns Prof Dr Ludwig |
Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
|
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
|
JPH10203966A
(ja)
|
1996-11-21 |
1998-08-04 |
Takeda Chem Ind Ltd |
徐放性マイクロカプセルおよびその製造法
|
|
US6392104B1
(en)
|
1997-03-11 |
2002-05-21 |
Daicel Chemical Industries, Ltd. |
Adamantane derivatives and process for producing them
|
|
US5849800A
(en)
*
|
1997-03-28 |
1998-12-15 |
The Penn State Research Foundation |
Use of amantadine for treatment of Hepatitis C
|
|
ATE219044T1
(de)
|
1997-04-10 |
2002-06-15 |
Pfizer |
Fluorosubstituierte adamantan-derivate
|
|
MY125849A
(en)
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
|
MA26553A1
(fr)
|
1997-10-17 |
2004-12-20 |
Centaur Pharmaceuticals Inc |
Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
|
|
FR2772615B1
(fr)
|
1997-12-23 |
2002-06-14 |
Lipha |
Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
|
|
US6251430B1
(en)
*
|
1998-02-04 |
2001-06-26 |
Guohua Zhang |
Water insoluble polymer based sustained release formulation
|
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
|
PE20000728A1
(es)
|
1998-06-26 |
2000-08-21 |
Cocensys Inc |
Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
|
|
WO2000035419A2
(en)
|
1998-12-17 |
2000-06-22 |
Alza Corporation |
Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
|
|
US6962717B1
(en)
|
1999-01-29 |
2005-11-08 |
Disphar International B.V. |
Pharmaceutical compositions
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
NZ514442A
(en)
|
1999-03-03 |
2003-08-29 |
Optinose As |
Nasal delivery device
|
|
SE9901077D0
(sv)
|
1999-03-23 |
1999-03-23 |
Astra Ab |
Novel use
|
|
US6183770B1
(en)
|
1999-04-15 |
2001-02-06 |
Acutek International |
Carrier patch for the delivery of agents to the skin
|
|
US6743211B1
(en)
|
1999-11-23 |
2004-06-01 |
Georgia Tech Research Corporation |
Devices and methods for enhanced microneedle penetration of biological barriers
|
|
CN100391438C
(zh)
|
1999-09-14 |
2008-06-04 |
史密丝克莱恩比彻姆公司 |
制备水性包被小球粒的方法
|
|
AU764453B2
(en)
|
1999-10-29 |
2003-08-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
AU2084801A
(en)
*
|
1999-12-09 |
2001-06-18 |
Alza Corporation |
Antiviral medication
|
|
AU781839B2
(en)
|
1999-12-22 |
2005-06-16 |
Nektar Therapeutics |
Sterically hindered derivatives of water soluble polymers
|
|
US6753011B2
(en)
|
2000-01-14 |
2004-06-22 |
Osmotica Corp |
Combined diffusion/osmotic pumping drug delivery system
|
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
|
US6444702B1
(en)
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
|
US6455066B1
(en)
|
2000-03-10 |
2002-09-24 |
Epicept Corporation |
Intradermal-penetration agents for topical local anesthetic administration
|
|
BR0116001A
(pt)
|
2000-12-07 |
2004-07-06 |
Neuromolecular Inc |
Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
|
|
US20040122090A1
(en)
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
|
NZ527832A
(en)
†
|
2001-03-13 |
2006-03-31 |
Penwest Pharmaceuticals Co |
Chronotherapeutic dosage forms
|
|
US20060198815A1
(en)
|
2001-03-19 |
2006-09-07 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained release
|
|
EP1389181A4
(en)
|
2001-04-02 |
2005-10-19 |
Panorama Res Inc |
NITROXIDE AND NITRONE ANTIOXIDANTS AS THERAPEUTICS
|
|
DE10129265A1
(de)
|
2001-06-18 |
2003-01-02 |
Hf Arzneimittelforsch Gmbh |
Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
|
|
US20030045577A1
(en)
*
|
2001-08-15 |
2003-03-06 |
Madhat Maher N. |
Method for preventing infectious respiratory diseases
|
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
|
US20030118647A1
(en)
*
|
2001-12-04 |
2003-06-26 |
Pawan Seth |
Extended release tablet of metformin
|
|
US20050271708A1
(en)
|
2002-03-05 |
2005-12-08 |
Thombre Avinash G |
Palatable controlled-release formulation for companion animals
|
|
JP2005526079A
(ja)
|
2002-03-15 |
2005-09-02 |
サイプレス バイオサイエンス， インコーポレイテッド |
内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
|
|
DE60322371D1
(de)
|
2002-03-29 |
2008-09-04 |
Alza Corp |
Volumensparende arzneiform zur kontrollierten freisetzung
|
|
WO2004034963A2
(en)
|
2002-05-17 |
2004-04-29 |
Eisai Co., Ltd. |
Methods and compositions using cholinesterase inhibitors
|
|
US20040102525A1
(en)
|
2002-05-22 |
2004-05-27 |
Kozachuk Walter E. |
Compositions and methods of treating neurological disease and providing neuroprotection
|
|
WO2003101458A1
(en)
|
2002-05-31 |
2003-12-11 |
H. Lundbeck A/S |
A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
|
|
DE10224170A1
(de)
|
2002-05-31 |
2003-12-11 |
Desitin Arzneimittel Gmbh |
Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
|
|
US6945952B2
(en)
|
2002-06-25 |
2005-09-20 |
Theraject, Inc. |
Solid solution perforator for drug delivery and other applications
|
|
MXPA05000224A
(es)
|
2002-06-26 |
2005-06-03 |
Alza Corp |
Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
|
|
US20050208132A1
(en)
*
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
|
AU2003260336C1
(en)
|
2002-07-29 |
2008-05-29 |
Glaxo Group Limited |
Sustained release formulations comprising lamotrigine
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
DE10237082B4
(de)
*
|
2002-08-09 |
2014-12-31 |
Sartorius Stedim Biotech Gmbh |
Verfahren und Vorrichtung zur biotechnologischen Herstellung von Wertstoffen
|
|
EP1558231A4
(en)
|
2002-10-03 |
2010-09-08 |
Cypress Bioscience Inc |
DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
|
|
KR100777904B1
(ko)
|
2002-10-24 |
2007-11-28 |
메르츠 파마 게엠베하 운트 코. 카가아 |
1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
|
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
US20060024366A1
(en)
|
2002-10-25 |
2006-02-02 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
US20040097484A1
(en)
|
2002-11-14 |
2004-05-20 |
Marc Cantillion |
Once a day galantamine pharmaceutical compositions and methods of use
|
|
US20100092562A1
(en)
|
2002-11-26 |
2010-04-15 |
Hollenbeck R Gary |
Sustained-release drug delivery compositions and methods
|
|
EP1572164A2
(en)
*
|
2002-12-18 |
2005-09-14 |
Pain Therapeutics, Inc. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
|
AU2003302147A1
(en)
*
|
2002-12-23 |
2004-07-14 |
Osmotica Costa Rica Sociedad Anonima |
Delivery device containing venlafaxine and memantine and use method thereof
|
|
US20050031651A1
(en)
|
2002-12-24 |
2005-02-10 |
Francine Gervais |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
|
US20040185097A1
(en)
|
2003-01-31 |
2004-09-23 |
Glenmark Pharmaceuticals Ltd. |
Controlled release modifying complex and pharmaceutical compositions thereof
|
|
AR043467A1
(es)
|
2003-03-05 |
2005-07-27 |
Osmotica Argentina S A |
Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
|
|
US20050065219A1
(en)
|
2003-03-27 |
2005-03-24 |
Lipton Stuart A. |
Treatment of demyelinating conditions
|
|
WO2005019166A2
(en)
|
2003-06-11 |
2005-03-03 |
Neuromolecular, Inc. |
Method of targeting a therapeutic agent
|
|
PL378902A1
(pl)
|
2003-06-16 |
2006-05-29 |
Allergan, Inc. |
Doustne postaci użytkowe memantyny
|
|
AU2004273958A1
(en)
|
2003-09-19 |
2005-03-31 |
Penwest Pharmaceuticals Co. |
Chronotherapeutic dosage forms
|
|
EA200600598A1
(ru)
|
2003-09-19 |
2006-08-25 |
Пенвест Фармасьютикалз Ко. |
Лекарственные формы замедленного высвобождения
|
|
WO2005051389A1
(en)
|
2003-11-21 |
2005-06-09 |
Memory Pharmaceuticals Corporation |
Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders
|
|
US20050119249A1
(en)
|
2003-12-02 |
2005-06-02 |
Erik Buntinx |
Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
WO2005065645A2
(en)
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Donepezil formulations
|
|
CA2551946A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Immediate, controlled and sustained release formulations of galantamine
|
|
WO2005072125A2
(en)
|
2004-01-16 |
2005-08-11 |
Massachusetts Institute Of Technology |
Composite materials for controlled release of water soluble products
|
|
WO2005072705A1
(en)
|
2004-01-29 |
2005-08-11 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
|
|
EP1734920A2
(en)
*
|
2004-02-13 |
2006-12-27 |
Neuromolecular Inc. |
Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
|
|
CA2556214A1
(en)
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
|
WO2005079851A2
(en)
*
|
2004-02-18 |
2005-09-01 |
Sepracor, Inc. |
Dopamine-agonist combination therapy with sedatives for improving sleep quality
|
|
CA2569015A1
(en)
*
|
2004-06-17 |
2006-01-26 |
Forest Laboratories, Inc. |
Modified release formulation of memantine
|
|
WO2006017159A1
(en)
|
2004-07-09 |
2006-02-16 |
Drugtech Corporation |
Controlled phase composition technology as an improved process for protection of drugs
|
|
US8609198B2
(en)
*
|
2004-07-21 |
2013-12-17 |
Hewlett-Packard Development Company, L.P. |
Pharmaceutical dose form with a patterned coating and method of making the same
|
|
EP1789028A2
(en)
*
|
2004-08-24 |
2007-05-30 |
Neuromolecular Pharmaceuticals Inc |
Compositions for treating nociceptive pain
|
|
US20060240043A1
(en)
*
|
2004-10-08 |
2006-10-26 |
Meyerson Laurence R |
Methods and compositions for treating migraine pain
|
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
|
EP1827385B1
(en)
*
|
2004-11-23 |
2013-03-27 |
Adamas Pharmaceuticals, Inc. |
Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
|
|
US8389578B2
(en)
|
2004-11-24 |
2013-03-05 |
Adamas Pharmaceuticals, Inc |
Composition and method for treating neurological disease
|
|
US8574626B2
(en)
*
|
2004-12-03 |
2013-11-05 |
Osmotica Kereskedelmi és Szolgáltató KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
|
US8252331B2
(en)
*
|
2004-12-03 |
2012-08-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
US20090208579A1
(en)
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
|
WO2006081518A2
(en)
|
2005-01-28 |
2006-08-03 |
Collegium Pharmaceutical, Inc. |
Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
|
|
US20080279819A1
(en)
*
|
2005-02-15 |
2008-11-13 |
Adamas Pharmaceuticals, Inc. |
Combinations Therapy for Treatment of Demyelinating Conditions
|
|
JP5666087B2
(ja)
|
2005-04-06 |
2015-02-12 |
アダマス・ファーマシューティカルズ・インコーポレーテッド |
Ｃｎｓ関連疾患の治療のための方法及び組成物
|
|
US20060280795A1
(en)
|
2005-06-08 |
2006-12-14 |
Dexcel Pharma Technologies, Ltd. |
Specific time-delayed burst profile delivery system
|
|
WO2007036952A2
(en)
|
2005-07-01 |
2007-04-05 |
Rubicon Research Pvt Ltd. |
Novel sustained release dosage form
|
|
US7951760B2
(en)
*
|
2005-07-29 |
2011-05-31 |
Chevron Oronite S.A. |
Overbased alkali metal alkylhydroxybenzoates having low crude sediment
|
|
US20080248107A1
(en)
|
2005-08-24 |
2008-10-09 |
Rubicon Research Pvt. Ltd. |
Controlled Release Formulation
|
|
WO2007056424A2
(en)
|
2005-11-07 |
2007-05-18 |
Penwest Pharmaceuticals, Co. |
Controlled-release emulsion compositions
|
|
CA2648280C
(en)
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
|
CA2652576A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of viral infections
|
|
US20080089861A1
(en)
*
|
2006-07-10 |
2008-04-17 |
Went Gregory T |
Combination therapy for treatment of demyelinating conditions
|
|
ATE510538T1
(de)
*
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
|
KR101575679B1
(ko)
|
2006-08-30 |
2015-12-08 |
자고텍 아게 |
코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
|
|
EP1961414A1
(en)
|
2007-02-21 |
2008-08-27 |
FUJIFILM Manufacturing Europe B.V. |
A controlled release composition comprising a recombinant gelatin
|
|
US7981930B2
(en)
|
2007-03-13 |
2011-07-19 |
Adamas Pharmaceuticals, Inc. |
Compositions and kits for treating influenza
|
|
EP2322168A1
(en)
*
|
2007-04-02 |
2011-05-18 |
Parkinson's Institute |
Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
|
|
JP2010525018A
(ja)
|
2007-04-24 |
2010-07-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
|
|
EP1987815A1
(en)
*
|
2007-05-04 |
2008-11-05 |
Schwarz Pharma Ag |
Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
|
|
CA2689101C
(en)
|
2007-05-30 |
2013-01-22 |
Neos Therapeutics, Lp |
Modifying drug release in suspensions of ionic resin systems
|
|
US8821928B2
(en)
|
2007-06-04 |
2014-09-02 |
Egalet Ltd. |
Controlled release pharmaceutical compositions for prolonged effect
|
|
US8637080B2
(en)
|
2007-06-28 |
2014-01-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Rupturing controlled release device comprising a subcoat
|
|
US20090041820A1
(en)
|
2007-08-07 |
2009-02-12 |
Wu Margaret M |
Functional polymer compositions
|
|
SI2187875T1
(sl)
|
2007-09-21 |
2012-12-31 |
Evonik Rohm Gmbh |
Od pH odvisen farmacevtski sestavek z nadzorovanim sproščanjem za ne-opioide z odpornostjo na vpliv etanola
|
|
WO2009099831A2
(en)
|
2008-01-31 |
2009-08-13 |
Mcneil-Ppc, Inc. |
Edible film-strips with modified release active ingredients
|
|
JP2010040238A
(ja)
*
|
2008-08-01 |
2010-02-18 |
Panasonic Corp |
プラズマディスプレイパネルの製造方法
|
|
AU2009281537A1
(en)
|
2008-08-14 |
2011-06-30 |
Bioneer A/S |
Coated tablets with a remaining degradation surface over the time
|
|
US20100159001A1
(en)
|
2008-12-19 |
2010-06-24 |
Cardinal John R |
Extended-Release Pharmaceutical Formulations
|
|
US20100221328A1
(en)
*
|
2008-12-31 |
2010-09-02 |
Wertz Christian F |
Sustained-release formulations
|
|
US20130059008A1
(en)
|
2009-01-23 |
2013-03-07 |
Jeffrey L. Atkinson |
Drying methods for tuning microparticle properties
|
|
SI2408436T1
(sl)
|
2009-03-18 |
2017-06-30 |
Evonik Roehm Gmbh |
Farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola, ki uporablja oplaščenje, ki vsebuje nevtralne vinil polimere in ekscipiente
|
|
CA2756386C
(en)
|
2009-03-23 |
2019-01-15 |
Micell Technologies, Inc. |
Drug delivery medical device
|
|
WO2010115015A1
(en)
|
2009-04-03 |
2010-10-07 |
Coating Place, Inc. |
Modified-release pharmaceutical drug composition
|
|
MX365650B
(es)
|
2009-12-02 |
2019-06-10 |
Adamas Pharmaceuticals Inc |
Composiciones de amantadina y metodos para su uso.
|
|
GB201003766D0
(en)
|
2010-03-05 |
2010-04-21 |
Univ Strathclyde |
Pulsatile drug release
|
|
EP2706641A1
(en)
|
2012-09-05 |
2014-03-12 |
Siemens Aktiengesellschaft |
Method to provide primary control power by an energy storage system
|
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
|
CA3072764A1
(en)
|
2017-08-24 |
2019-02-28 |
Adamas Pharma, Llc |
Amantadine compositions, preparations thereof, and methods of use
|